Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 130

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Glofitamab in Patients with R/R DLBCL in Real Life Setting - a Retrospective Study

Ronit Gurion, Dmitri Guz, Meirav Kedmi, Chava Perry, Irit Avivi Mazza, Netanel A. Horowitz, Uri Abadi, Anat Gafter-Gvili, Pia Raanani, Neta Goldschmidt, Boaz Nachmias, Shlomzion Aumann

Blood (2023) 142 (Supplement 1): 5170.

https://doi.org/10.1182/blood-2023-186033

Published: 2023

Journal Articles

Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis

Eyal Lebel, Shlomit Kfir-Erenfeld, Nathalie Asherie, Sigal Grisariu, Batia Avni, Shlomo Elias, Miri Assayag, Tatyana Dubnikov, Nomi Zalcman, Marjorie Pick, Eran Zimran, Yael C. Cohen, Irit Avivi Mazza, Cyrille Cohen, Polina Stepensky, Moshe E Gatt

Blood (2023) 142 (Supplement 1): 538.

https://doi.org/10.1182/blood-2023-186450

Published: 2023

Journal Articles

Towards a Decision Engine for Therapeutic Optimization of Relapsed Refractory Multiple Myeloma

Yael C. Cohen, Mor Zada, Shuang-Yin Wang, Assaf Weiner, Natan Melamed, Polina Stepensky, Moshe E Gatt, Shlomit Kfir-Erenfeld, Nathalie Asherie, Eyal Lebel, Irit Avivi Mazza, Anna Gurevich Shapiro, Iuliana Vaxman, Tamir Shragai, Paulina Chalan, Eyal David, Ido Amit

Blood (2023) 142 (Supplement 1): 341.

https://doi.org/10.1182/blood-2023-190178

Published: 2023

Journal Articles

Determinants of Response to Anti CD-19 CAR-T Cells for Diffuse Large B-Cell Lymphoma in Pre-Treatment Peripheral Blood Mononuclear Cells Using Single-Cell RNA-Seq

Ron Ram, Yonatan Katzenelenbogen, Anna Gurevich Shapiro, Eitan Winter, Oren Barboy, Mor Zada, Shahar Halevi, Eyal David, Irit Avivi Mazza, Ido Amit

Blood (2023) 142 (Supplement 1): 4829.

https://doi.org/10.1182/blood-2023-190639

Published: 2023

Journal Articles

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Active Primary Malignancy at HCT - a Bi-Institutional Retrospective Cohort Analysis

Ron Ram, Ido Wolf, Odelia Amit, Ronit Yerushalmi, Yakir Moshe, Noga Shem-Tov, Gil Fridberg, Ivetta Danylesko, Irit Avivi Mazza, Avichai Shimoni

Blood (2023) 142 (Supplement 1): 3590.

https://doi.org/10.1182/blood-2023-182826

Published: 2023

Journal Articles

Outcomes of Acute Myeloid Leukemia Patients Suffering from an Additional Active Malignancy Treated with Venetoclax and Azacitidine: A Single Center Experience

Yakir Moshe, Shai Levi, Miriam Neaman, Roi Gat, Mor Levi, Nili Eilati, Gil Fridberg, Yotam Bornstein, Tamir Shragai, Tsipora Neuman, Roy Vitkon, Eliya Shachar, David Sarid, Ofer Merimsky, Moshe Mittelman, Irit Avivi Mazza

Blood (2023) 142 (Supplement 1): 5929.

https://doi.org/10.1182/blood-2023-186234

Published: 2023

Journal Articles

A Novel Approach to Epigenetic Profiling in Acute Myeloid Leukemia: Mapping Methylation and Hydroxymethylation in Genomic and Cell-Free DNA

Miriam Neaman, Mika Bell, Jasline Deek, Irit Avivi Mazza, Yakir Moshe, Yael Michaeli, Noa Gilat, Gal Mesika Surizon, Topaz Kreiser Shem Tov, Metsada Pasmanik Chor, Yuval Ebenstein

Blood (2023) 142 (Supplement 1): 6011.

https://doi.org/10.1182/blood-2023-189737

Published: 2023

Journal Articles

Subcutaneous Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma from EPCORE NHL-5

Irit Avivi Mazza, Won Seog Kim, Po-Shen Ko, Carlos Grande, David Lavie, David Chism, Mostafa Seliem, Edwin E. Jeng, Neha Joshi, Satya Siddani, Wissam Assaily, Mariana Sacchi, Minh Dinh, Abraham Avigdor

Blood (2023) 142 (Supplement 1): 438.

https://doi.org/10.1182/blood-2023-180089

Published: 2023

Journal Articles

A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed and/or Refractory B-Cell Malignancies

Blood (2023) 142 (Supplement 1): 3099.

https://doi.org/10.1182/blood-2023-179061

Published: 2023

Journal Articles

Second Vs Third Line Treatment with Axicabtagene Ciloleucel for Large B Cell Lymphoma - a Real-Life National Multicenter Retrospective Cohort Study with Propensity Score Matching

Gil Fridberg, Odelia Amit, Liat Shargian, Ofrat Beyar Katz, Sigal Grisariu, Chava Perry, Ronit Gurion, Batia Avni, Tsila Zuckerman, Irit Avivi Mazza, Ron Ram

Blood (2023) 142 (Supplement 1): 4886.

https://doi.org/10.1182/blood-2023-188473

Published: 2023

Journal Articles

Smoldering Multiple Myeloma Progressing to Active Multiple Myeloma Vs De-Novo Active Multiple Myeloma - a Comparison of Disease Characteristics, Organ Involvement and Outcomes in a Real-Life Multicenter Retrospective Cohort Study

Yael C. Cohen, Gil Fridberg, Inbar Cohen, Renana Robinson, Iuliana Vaxman, Tamir Shragai, Svetlana Trestman, Tomer Ziv-Baran, Natan Melamed, Pia Raanani, Irit Avivi Mazza

Blood (2023) 142 (Supplement 1): 4728.

https://doi.org/10.1182/blood-2023-186140

Published: 2023

Journal Articles

Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 Study

Jennifer L. Crombie, Matthew Matasar, Max S. Topp, John N. Allan, Jeffrey A. Barnes, Jon E. Arnason, Jean-Marie Michot, Neta Goldschmidt, Susan M. O'Brien, Uri Abadi, Irit Avivi Mazza, Jessica Cai, Dina M. Flink, Min Zhu, Jurriaan Brouwer-Visser, Hesham Mohamed, Aafia Chaudhry, Srikanth Ambati, Steve M Ansell

Blood (2023) 142 (Supplement 1): 4461.

https://doi.org/10.1182/blood-2023-181602

Published: 2023

Journal Articles

Safety and Efficacy of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma

Eyal Lebel, Nathalie Asherie, Shlomit Kfir-Erenfeld, Batia Avni, Sigal Grisariu, Shlomo Elias, Miri Assayag, Tatyana Dubnikov, Nomi Zalcman, Marjorie Pick, Eran Zimran, Yael C. Cohen, Irit Avivi Mazza, Cyrille Cohen, Moshe E Gatt, Polina Stepensky

Blood (2023) 142 (Supplement 1): 4852.

https://doi.org/10.1182/blood-2023-185069

Published: 2023

Journal Articles

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)

Yael C. Cohen, Tamir Shragai, Noa Lavi, Iuliana Vaxman, Evgeni Chubar, Moshe E Gatt, Chezi Ganzel, Hila Magen, Efrat Luttwak, Moshe Mittelman, Inna Tzoran, Vladimir Vainstein, Noa Lowenton-Spier, Natan Melamed, Ella Krayzler, Ilana Pereg, Irit Avivi Mazza

Blood (2023) 142 (Supplement 1): 2014.

https://doi.org/10.1182/blood-2023-185830

Published: 2023

Journal Articles

Unraveling the Mechanism of Action of Bispecific T-Cell Engagers in B-Cell Acute Lymphoblastic Leukemia Using Advanced Single-Cell Multiomics

Anna Gurevich Shapiro, Eitan Winter, Yakir Moshe, Yonatan Katzenelenbogen, Diego Jaitin, Mor Zada, Oren Barboy, Ido Yofe, Paulina Chalan, San Truong Phan, Amir Giladi, Michael Shapiro, Renana Robinson, Eitan Kugler, Ofir Wolach, Irit Avivi Mazza, Ido Amit

Blood (2023) 142 (Supplement 1): 599.

https://doi.org/10.1182/blood-2023-188930

Published: 2023

Journal Articles

Belantamab Mafodotin in Relapse/Refractory AL Amyloidosis- Real-Life Multi-Center Experience

Eyal Lebel, Vladimir Vainstein, Paolo Milani, Giovanni Palladini, Tamir Shragai, Noa Lavi, Hila Magen, Assayag Miri, Irit Avivi Mazza, Moshe E Gatt

Blood (2023) 142 (Supplement 1): 6763.

https://doi.org/10.1182/blood-2023-173317

Published: 2023

Journal Articles

Clinical Significance of a Slightly Abnormal FLC Levels/Ratio

Dor Shpitzer, Yael C. Cohen, Chava Perry, Anat Reiner-Benaim, Irit Avivi Mazza

Blood (2023) 142 (Supplement 1): 4777.

https://doi.org/10.1182/blood-2023-188508

Published: 2023

Journal Articles

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Blood (2023) 141 (3): 219–230.

https://doi.org/10.1182/blood.2022015526

Published: 2023

Includes: Supplemental data

Journal Articles

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Blood (2022) 140 (21): 2248–2260.

https://doi.org/10.1182/blood.2022015478

Published: 2022

Includes: Supplemental data

Journal Articles

Sequential Therapy Vs. Salvage Chemotherapy for Patients with AML Refractory to First Induction Regimen- a Bi-Institutional Retrospective Cohort Analysis

Ron Ram, Odelia Amit, Shai Winer, Yakir Moshe, Pia Raanani, Eitan Kugler, Moshe Yeshurun, Irit Avivi, Ofir Wolach

Blood (2022) 140 (Supplement 1): 10637–10638.

https://doi.org/10.1182/blood-2022-164543

Published: 2022

NARROW

Efficacy and Safety of Glofitamab in Patients with R/R DLBCL in Real Life Setting - a Retrospective Study

Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis

Towards a Decision Engine for Therapeutic Optimization of Relapsed Refractory Multiple Myeloma

Determinants of Response to Anti CD-19 CAR-T Cells for Diffuse Large B-Cell Lymphoma in Pre-Treatment Peripheral Blood Mononuclear Cells Using Single-Cell RNA-Seq

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Active Primary Malignancy at HCT - a Bi-Institutional Retrospective Cohort Analysis

Outcomes of Acute Myeloid Leukemia Patients Suffering from an Additional Active Malignancy Treated with Venetoclax and Azacitidine: A Single Center Experience

A Novel Approach to Epigenetic Profiling in Acute Myeloid Leukemia: Mapping Methylation and Hydroxymethylation in Genomic and Cell-Free DNA

Subcutaneous Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma from EPCORE NHL-5

A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed and/or Refractory B-Cell Malignancies

Second Vs Third Line Treatment with Axicabtagene Ciloleucel for Large B Cell Lymphoma - a Real-Life National Multicenter Retrospective Cohort Study with Propensity Score Matching

Smoldering Multiple Myeloma Progressing to Active Multiple Myeloma Vs De-Novo Active Multiple Myeloma - a Comparison of Disease Characteristics, Organ Involvement and Outcomes in a Real-Life Multicenter Retrospective Cohort Study

Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 Study

Safety and Efficacy of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)

Unraveling the Mechanism of Action of Bispecific T-Cell Engagers in B-Cell Acute Lymphoblastic Leukemia Using Advanced Single-Cell Multiomics

Belantamab Mafodotin in Relapse/Refractory AL Amyloidosis- Real-Life Multi-Center Experience

Clinical Significance of a Slightly Abnormal FLC Levels/Ratio

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Sequential Therapy Vs. Salvage Chemotherapy for Patients with AML Refractory to First Induction Regimen- a Bi-Institutional Retrospective Cohort Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only